The rise of GLP-1 therapies has rapidly expanded from a clinical niche into a widely adopted category, with millions of users and surging demand positioning them at the center of today’s metabolic health landscape. Lance Converse, founder of Tonum, believes the conversation has moved quickly, but not completely. “The industry has focused intensely on access and outcomes in the near term,” he says. “What remains largely unaddressed is the long-term metabolic picture and what happens when treatment is discontinued.” For women between the ages of 45 and 60, he notes, this question carries added weight. He explains, “This stage is characterized by hormonal changes alongside declines in muscle mass and bone density. As interest in GLP-1 therapies has surged within this demographic, so too has the need for a more complete framework that extends beyond initial results.” Converse points to a growing body of evidence that suggests that a meaningful proportion of the reduction associated with GLP-1 use can come from lean mass, including muscle and bone density. While estimates vary across studies, he notes, the pattern is consistent enough to warrant attention, particularly for populations already vulnerable to age-related muscle decline. “Muscle is not just about strength or appearance,” he explains. “It is a primary driver of metabolic activity. The more muscle you carry, the more efficiently your body utilizes energy at rest. When that declines, the metabolic system becomes less resilient.” GLP-1 therapies primarily work by regulating appetite and food intake. Their effects on body composition and metabolism are largely indirect, driven by reduced caloric intake rather than direct mechanisms targeting muscle preservation or conditioning. According to Converse, this creates a potential imbalance for certain users, especially those navigating postmenopausal changes. “It is possible for someone to see progress on the scale while moving in the wrong direction metabolically,” he says. “That is the nuance we need to bring into the conversation.” This is where Converse sees an emerging gap. He emphasizes that the current narrative emphasizes initiation, and less attention is given to continuity, transition, and sustainability. Converse believes that Tonum’s work is positioned around that gap. The company’s early focus was cognitive health, with research centered on neuroprotection and long-term brain function. Its formulation, motus, supported by clinical research and publications, was not originally designed for body composition. “What we discovered during development was unexpected,” Converse says. “The same pathways we were exploring for brain health showed meaningful effects on metabolic processes. That insight led us to build two distinct formulations, one for metabolic support and one for cognitive health.” The result, he adds, is a dual approach that reflects the interconnected nature of metabolism and brain function. Unlike GLP-1, Converse believes that motus does not act as an appetite suppressant but has a different mechanism of action that is designed to boost metabolism. Yet he is careful in how he frames its role within the broader GLP-1 landscape. “This is not about replacement or competition,” he says. “It is about expanding the conversation and offering additional pathways that individuals and clinicians can consider.” From his perspective, there are three key considerations shaping the next phase of this category. The first, he says, is decision clarity. As more individuals explore GLP-1 therapies, there is a need for a more personalized understanding of who they are best suited for, particularly in later life stages. The second is transition planning. For those who choose to discontinue use, the absence of a structured off-ramp can lead to uncertainty. Converse believes this phase deserves as much attention as the initiation phase. “We need to think about continuity of metabolic support,” he says. “The system does not reset overnight. There has to be a strategy for what comes after.” The third is optimization. Some individuals may remain on GLP-1 therapies in the long term. In these cases, Converse sees potential in exploring different approaches, combined with broader metabolic support strategies, that might evolve over time. He frames this as an area for ongoing research rather than a defined conclusion. According to him, underlying all three considerations is a consistent theme: The future of metabolic health will depend less on singular solutions and more on integrated thinking. Converse brings more than three decades of experience in pharmaceutical and clinical research environments to this perspective. His career has been shaped by building and scaling organizations that operate at the intersection of science and application. That background informs his emphasis on measured, evidence-based progress. “We are still early in understanding the full impact of this category,” he says. “The pace of adoption has outstripped the pace of long-term insight.” As the GLP-1 era continues to unfold, Converse believes the next phase will likely be defined by a deeper exploration of sustainability. For him, this includes muscle preservation, metabolic resilience, cognitive health, and the practical realities of long-term use and discontinuation. Converse highlights that his goal is not to slow momentum. It is to refine direction. “Innovation does not end with a breakthrough,” he says. “It begins there. The real responsibility is to understand how that breakthrough fits into the full arc of human health.” The post Beyond the GLP-1 Surge: Rethinking Metabolic Health for the Long Term appeared first on LA Weekly. ...read more read less